Yüksel Ürün
@DrYukselUrun
Prof. Medical Oncologist 🔬 @AnkaraUni 🎓 Advocate for #Diversity & #Equity 🌟 Genitourinary Cancer I 2023-2024 @ASCO Leadership Development Program
ID:2798480350
https://yukselurun.com/ 01-10-2014 17:42:21
10,4K Tweets
6,5K Followers
575 Following
Follow People
İşte yaşlanma sürecinde ❤️ ve metabolik sağlığınızı korumak için başvurabileceğiniz kanıta dayalı:
🔟 strateji!
EHJ Editor-in-Chief Melike Şahin European Society of Cardiology Journals #MedTwitter T.C. Sağlık Bakanlığı Ankara Üniversitesi Ankara Büyükşehir
⭐️CheckMate 901 update by Dr. Guru Sonpavde Guru P. Sonpavde, MD #AUA24 Cis/Gem/Nivo vs Cis/Gem 1st line mUC cisplatin elig ✅OS👉HR 0.78
👇Cis/Gem/Nivo superior👇
✅ORR 57.6% vs 43.1%
✅CR 21.7% vs, 11.8%
✅Median CR duration 37.1 vs 13.2 mths
👇NEJM👇𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏
nejm.org/doi/pdf/10.105…
Conventional or modern imaging modalities for #prostatecancer in 2024?
Join us & discuss with Akash Maniam, MD 🇺🇦 from Portsmouth Hospitals University NHST in presence or virtually!
Register for free 👉ow.ly/yLoL50RyqgH
#IUCS24 #urology #oncology Giuseppe Banna Ravindran Kanesvaran
So proud of this project on 2 levels:
(1) It showcases the hard work of our superstar City of Hope fellow Hedyeh Ebrahimi
(2) It showcases OUTSTANDING mentorship from our junior faculty member Alex Chehrazi-Raffle, MD
In this piece (reflecting a collaboration w ACCC & Genentech), they…
Guru P. Sonpavde, MD presented exploratory analyses from the Checkmate 901 study at #AUA24 . Higher quantity and quality of complete responses with gem/cis/nivo versus gem/cis in patients with metastatic bladder cancer. #BladderCancerAwarenessMonth #bladdercancer #blcsm
Our efforts to find optimal combinations with fewer adverse events while maintaining effectiveness for our patients continue.
We are extremely pleased to be involved in this study as Ankara Üniversitesi
Thank you dear Neeraj Agarwal, MD, FASCO for presenting at #AUA24
OncoAlert Arun Azad…
#AUA24 Amer. Urol. Assn. 👉Dr. Neeraj Agarwal Neeraj Agarwal, MD, FASCO presents the EvoPAR-Prostate01 phase 3 trial (trial in progress) in mHSPC #ProstateCancer with ADT+ARPI plus/minus SARUPARIB, a novel PARP1 selective inhibitor. Trial design👇 OncoAlert UroToday.com PCF Science GU Cancer Research Program @HuntsmanCancer